These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 26713838)

  • 1. WITHDRAWN: Immunotherapy for advanced renal cell cancer.
    Coppin C; Porzsolt F; Autenrieth M; Kumpf J; Coldman A; Wilt TJ
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD001425. PubMed ID: 26713838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for advanced renal cell cancer.
    Coppin C; Porzsolt F; Awa A; Kumpf J; Coldman A; Wilt T
    Cochrane Database Syst Rev; 2005 Jan; (1):CD001425. PubMed ID: 15674877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for advanced renal cell cancer.
    Coppin C; Porzsolt F; Kumpf J; Coldman A; Wilt T
    Cochrane Database Syst Rev; 2000; (3):CD001425. PubMed ID: 10908496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunotherapy for advanced renal cell cancer].
    Schmidt S; Kunath F; Kroeger N
    Urologe A; 2015 May; 54(5):716-20. PubMed ID: 25987336
    [No Abstract]   [Full Text] [Related]  

  • 5. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma.
    Pantuck AJ; Belldegrun AS; Figlin RA
    N Engl J Med; 2001 Dec; 345(23):1711-2. PubMed ID: 11759660
    [No Abstract]   [Full Text] [Related]  

  • 6. Chemo-immunotherapy in RCC: the end of a story.
    Escudier B
    Lancet; 2010 Feb; 375(9715):613-4. PubMed ID: 20171385
    [No Abstract]   [Full Text] [Related]  

  • 7. Current clinical practice of induction and maintenance immunotherapy for metastatic renal cell carcinoma.
    Little B; Young M; Ho KJ
    Int J Clin Pract; 2002; 56(1):36-9. PubMed ID: 11831831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging immunotherapy in advanced renal cell carcinoma.
    Mendiratta P; Rini BI; Ornstein MC
    Urol Oncol; 2017 Dec; 35(12):687-693. PubMed ID: 28889919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete remission of extensive metastatic renal cancer following immunotherapy.
    Plowman PN; Costello J; O'Donoghue N
    Clin Oncol (R Coll Radiol); 1997; 9(3):176-80. PubMed ID: 9269551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Present achievements in the medical treatment of metastatic renal cell carcinoma.
    Ravaud A; Debled M
    Crit Rev Oncol Hematol; 1999 Jun; 31(1):77-87. PubMed ID: 10532192
    [No Abstract]   [Full Text] [Related]  

  • 11. In focus: bevacizumab for renal cell carcinoma.
    Clin Adv Hematol Oncol; 2005 Jan; 3(1):68-9. PubMed ID: 16166971
    [No Abstract]   [Full Text] [Related]  

  • 12. New challenges in kidney cancer therapy: bevacizumab.
    Ravaud A
    Ann Oncol; 2007 Jul; 18 Suppl 9():ix89. PubMed ID: 17631602
    [No Abstract]   [Full Text] [Related]  

  • 13. Removing the primary tumor after the cancer has spread.
    Tannock IF
    N Engl J Med; 2001 Dec; 345(23):1699-700. PubMed ID: 11759650
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of adoptive immunotherapy in solid cancers.
    Kruit WH; Stoter G
    Neth J Med; 1997 Feb; 50(2):47-68. PubMed ID: 9050332
    [No Abstract]   [Full Text] [Related]  

  • 15. Novel investigative approaches for advanced renal cell carcinoma.
    Berg WJ; Divgi CR; Nanus DM; Motzer RJ
    Semin Oncol; 2000 Apr; 27(2):234-9. PubMed ID: 10768602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel.
    Pouessel D; Culine S
    Expert Rev Anticancer Ther; 2006 Dec; 6(12):1761-7. PubMed ID: 17181490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive immunotherapy of renal cell carcinoma: studies from the Surgery Branch, National Cancer Institute.
    Linehan WM; Walther MM; Alexander RB; Rosenberg SA
    Semin Urol; 1993 Feb; 11(1):41-3. PubMed ID: 8465127
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunotherapy for renal cell carcinoma: the era of interleukin-2-based treatment.
    Taneja SS; Pierce W; Figlin R; Belldegrun A
    Urology; 1995 Jun; 45(6):911-24. PubMed ID: 7771023
    [No Abstract]   [Full Text] [Related]  

  • 19. Cytoreductive nephrectomy in the era of targeted molecular agents: is it time to consider presurgical systemic therapy?
    Margulis V; Wood CG
    Eur Urol; 2008 Sep; 54(3):489-92. PubMed ID: 18206292
    [No Abstract]   [Full Text] [Related]  

  • 20. Cytoreductive nephrectomy in metastatic renal cancer.
    Flanigan RC
    Curr Urol Rep; 2003 Feb; 4(1):36-40. PubMed ID: 12537937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.